Evidence map›Paper›PMID 32326897›Full record

ArticleBMC cancer2020

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.

Anne Marie McCarthy, Nitya Pradeep Kumar, Wei He, Susan Regan, Michaela Welch, Beverly Moy, A John Iafrate, Andrew T Chan, Aditya Bardia, Katrina Armstrong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Anne Marie McCarthyDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA. annemcc@pennmedicine.upenn.edu.
Nitya Pradeep KumarHarvard T H Chan School of Public Health, Boston, USA.
Wei HeDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Susan ReganDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Michaela WelchDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Beverly MoyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Andrew T ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.
Katrina ArmstrongDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Massachusetts General Hospital · USHarvard University · US

Funding

American Cancer Society 131052-MRSG-17-144-01-CCE
6 · The paper itself

Abstract

introductionThe relationships among PIK3CA mutations, medication use and tumor progression remains poorly understood. Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality. We assessed time to metastasis (TTM) and survival with respect to aspirin use and tumor PIK3CA mutations among women with metastatic breast cancer.

methodsPatients with hormone receptor positive, HER2 negative (HR+/HER2-) metastatic breast cancer treated in 2009-2016 who received tumor genotyping were included. Aspirin use between primary and metastatic diagnosis was extracted from electronic medical records. TTM and survival were estimated using Cox proportional hazards regression.

resultsAmong 267 women with metastatic breast cancer, women with PIK3CA mutated tumors had longer TTM than women with PIK3CA wildtype tumors (7.1 vs. 4.7 years, p = 0.008). There was a significant interaction between PIK3CA mutations and aspirin use on TTM (p = 0.006) and survival (p = 0.026). PIK3CA mutations were associated with longer TTM among aspirin non-users (HR = 0.60 95% CI:0.44-0.82 p = 0.001) but not among aspirin users (HR = 1.57 0.86-2.84 p = 0.139). Similarly, PIK3CA mutations were associated with reduced mortality among aspirin non-users (HR = 0.70 95% CI:0.48-1.02 p = 0.066) but not among aspirin users (HR = 1.75 95% CI:0.88-3.49 p = 0.110).

conclusionsAmong women who develop metastatic breast cancer, tumor PIK3CA mutations are associated with slower time to progression and mortality only among aspirin non-users. Larger studies are needed to confirm this finding and examine the relationship among aspirin use, tumor mutation profile, and the overall risk of breast cancer progression.

Indexed as

MutationAdultAnti-Inflammatory Agents, Non-SteroidalAntineoplastic Combined Chemotherapy ProtocolsAspirinBiomarkers, TumorBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentAnti-Inflammatory Agents, Non-SteroidalAspirinBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesPIK3CA protein, humanReceptors, EstrogenReceptors, ProgesteroneAspirinBreast cancerMetastasisPIK3CA

Identifiers

PMID32326897
PMCPMC7181475
OpenAlexW3020027579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.